Treatment of platelet derived growth factor related disorders such as cancers

US6331555A · kind A · utility

Assignees

• The Regents of the University of California · US
• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL
• Bio-Signal Group Corp. · US
• Sugen, Inc. · US
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Klaus-Peter Hirth · San Francisco, US
• Elaina Mann · San Leandro, US
• Laura Shawyer · San Francisco, US
• Axel Ullrich · Portola Valley, US
• Istvan Szekely · Szentendre, HU
• Tamas Bajor · Budapest, HU
• Janis Haimichael · Budapest, HU
• Laszlo Orfi · Budapest, HU
• Alex Levitzki · Jerusalem, IL
• Aviv Gazit · Jerusalem, IL
• Peng Cho Tang · Moraga, US
• Reiner Lammers · Lörrach, DE

Key dates

• Filing date: Jul 27, 1999
• Grant date: Dec 18, 2001
• Expiry date: Jul 27, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.